Four years since the onset of the COVID-19 pandemic, the search for effective treatments continues with renewed focus on existing medications. Recent analysis of inosine pranobex, published in the International Journal of Infectious Diseases, demonstrates that established antivirals may offer previously unexplored therapeutic benefits against SARS-CoV-2. The drug, used clinically for decades to treat various viral infections, has shown antiviral properties and immune-modulating effects that warrant further investigation. This timeline reflects the evolving pharmaceutical response to the pandemic, following major antiviral approvals including remdesivir in 2020 and monoclonal antibodies in 2021. As researchers continue developing novel treatments, examining existing approved medications presents a pragmatic approach to expanding therapeutic options. Read the full article on GMJ Newsroom.
Was this article helpful?
